生物谷报道：最近，科学家们发现30%-40%乳腺癌存活者表达乳腺癌相关基因，这些基因未来可能是这些患者基因靶向治疗最大的靶标。这种乳腺癌原癌基因在肿瘤组织中有非常高的检出率。这对治疗许多乳腺癌患者有着非常重要的意义。这项研究结果发表在最新一期的《Cell》杂志上。
旧的基因分类技术方法学使研究者区分两基因困难。。以前科学家们每次只能评估一种基因。但是新的实验技术每次可以评估上百种基因。研究人员通过对1，200的基因的筛选，发现5个符合要求的基因。与此同时，他们从患者肿瘤取出癌细胞，利用特殊方法分别关闭与已鉴别出的基因相同的基因，寻找那些对肿瘤细胞存活发挥关键作用基因。。他们发现这些基因不仅维持肿瘤细胞存活，而且在其过表达时还促进肿瘤的形成。其中与其他基因不同的是IKBKE在人类乳腺癌中明显高表达。这种新的乳腺癌易感基因在肿瘤的形成和发展中起着及其关键的作用。此基因不同于以往的乳腺癌易感基因BRCA1和BRCA2，是先天具有的。带有这些遗传变异的这些基因的女性会增加早发乳腺癌的风险。研究者仅在乳腺癌组织中发现这种正常的新基因IKBKE突变而在机体其他器官并未检测出来。一个国际公认的加拿大乳腺癌专家认为IKBKE对了解乳腺癌的形成和发展具有标志性的作用。
Figure 1. Activated MEK1 and AKT1 Cooperate to replace H-RASV12
AI microscopic (100–200 μm, gray), macroscopic (>200 μm, black) colonies, and tumor formation (number of tumors formed/tumor sites injected) are shown for HEK cells expressing hTERT, LT, ST, and the indicated genes. Error bars represent mean ±SD for three independent experiments.
原文出处：
Cell June 15, 2007: 129 (6)
Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogenep1065
Jesse S. Boehm, Jean J. Zhao, Jun Yao, So Young Kim, Ron Firestein, Ian F. Dunn, Sarah K. Sjostrom, Levi A. Garraway, Stanislawa Weremowicz, Andrea L. Richardson, Heidi Greulich, Carly J. Stewart, Laura A. Mulvey, Rhine R. Shen, Lauren Ambrogio, Tomoko Hirozane-Kishikawa, David E. Hill, Marc Vidal, Matthew Meyerson, Jennifer K. Grenier, Greg Hinkle, David E. Root, Thomas M. Roberts, Eric S. Lander, Kornelia Polyak, and William C. Hahn
[Summary] [Full Text] [PDF] [Supplemental Data][Comments]
相关基因：
IKBKE
Official Symbol IKBKE and Name: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon [Homo sapiens]
Other Aliases: RP11-534L20.1, IKK-i, IKKE, IKKI, KIAA0151, MGC125294, MGC125295, MGC125297
Other Designations: IKK-related kinase epsilon; inducible IkappaB kinase
Chromosome: 1; Location: 1q32.1
Annotation: Chromosome 1, NC_000001.9 (204710418..204736844)
MIM: 605048
GeneID: 9641
作者简介：
William C. Hahn, MD, PhD
Associate Professor of Medicine, Harvard Medical School
Department
Medical Oncology/Molecular and Cellular
Center/Program
Genitourinary Cancer
Contact Information
William C. Hahn, MD, PhD
Biography
Dr. Hahn received his MD and PhD from Harvard Medical School in 1994. He then completed clinical training in internal medicine at Massachusetts General Hospital and medical oncology at DFCI. He conducted his postdoctoral studies with Dr. Robert Weinberg at the Whitehead Institute and joined the faculty of DFCI and Harvard Medical School in 2001.
